UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
Commission File Number:
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECTION 7 - REGULATION FD
Item 7.01. | Regulation FD Disclosure. |
On February 2, 2022, Amedisys, Inc. (the “Company”) issued a press release announcing that it has signed a definitive agreement to acquire Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit |
Description | |
99.1 | Press Release dated February 2, 2022 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMEDISYS, INC. | ||
By: | /s/ Paul B. Kusserow | |
Paul B. Kusserow | ||
Chief Executive Officer and Chairman of the Board | ||
DATE: February 2, 2022 |
Exhibit 99.1
Amedisys Signs Definitive Agreement to Acquire
Evolution Health
BATON ROUGE, La., February 2, 2022 (GLOBE NEWSWIRE) Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, announced today that it has signed a definitive agreement to acquire Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati. Headquartered in Dallas, Texas, the company cares for more than 3,300 home health patients daily and employs more than 650 employees in 15 locations across Texas, Oklahoma and Ohio.
Under the terms of the transaction, expected to close in the first half of 2022, Amedisys will acquire 100 percent of the ownership interests in Evolution Health. Once complete, this will increase Amedisys home health access to more than 1.9 million Medicare enrollees and more than 690,000 Medicare Advantage enrollees in Texas, and more than 800,000 Medicare enrollees and more than 350,000 Medicare Advantage enrollees in Ohio. Post-closing, Amedisys will provide both home health and hospice services to six communities across Texas, including Dallas/Fort Worth, San Antonio and Houston, furthering our strategy to become the solution for those who want to age in place.
By continuing the great care provided by Evolution Health, Amedisys will provide additional scale and resources that will expand our opportunities to care for more patients and in more communities across Texas, Oklahoma and Ohio, said Amedisys President and Chief Operating Officer Chris Gerard. Amedisys is proud to expand its presence in these healthcare communities and provide more comprehensive care by aligning with our Amedisys Hospice footprint in Texas.
The purchase of Evolution Health continues our strategy to acquire and integrate high-quality regional home health assets into our home health division, which leads the industry in quality, said Amedisys Chairman and Chief Executive Officer Paul Kusserow.
The transaction adds greater scale to Amedisys high-quality, nationwide network of 331 home health care centers. Post-closing, the combined home health operations will include 346 care centers in 34 states and the District of Columbia, with an average daily census of approximately 73,499 patients and approximately 11,236 home health employees.
Both Evolution Health and Amedisys share a commitment to providing quality care to our patients in the comfort of their homes, said Evolution Health President Mike Parsons. We look forward to growing with Amedisys and continuing to offer our employees exceptional resources and support to care for their patients, along with access to expanded service offerings.
In 2021, Modern Healthcare named Amedisys, Inc. to its prestigious Best Places to Work in Healthcare list. Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States with 528 locations across 38 states and the District of Columbia. As of the January 2022 Home Health Compare release, Amedisys Quality of Patient Care (QPC) Star score is 4.33. The Company also provides personal care, palliative care and high-acuity care.
Media Contact: |
Investor Contact: | |
Kendra Kimmons | Nick Muscato | |
Vice President of Marketing & Communications | Vice President of Strategic Finance | |
225-299-3708 | 615-928-5452 | |
kendra.kimmons@amedisys.com | nick.muscato@amedisys.com |
About Evolution Health
Evolution Health is a home health company headquartered in Dallas, Texas, serving three states through its family of trusted local brands. Working in partnership with the patients physician, Evolution Health offers traditional home health services reimbursed by Medicare, Medicaid and commercial payers including skilled nursing, occupational, physical and speech therapy, counseling and emotional support. Evolution Healths highest priority is to provide quality, compassionate care to its patients, their families, and the communities in which they serve. For more information, visit https://www.evolution.net/.
About Amedisys:
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 528 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.
Forward-Looking Statements:
When included in this press release, words like believes, belief, expects, strategy, plans, anticipates, intends, projects, estimates, may, might, could, would, should and similar expressions are intended to identify forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (COVID-19), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
# # #
Document and Entity Information |
Feb. 02, 2022 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | AMEDISYS INC |
Amendment Flag | false |
Entity Central Index Key | 0000896262 |
Document Type | 8-K |
Document Period End Date | Feb. 02, 2022 |
Entity File Number | 0-24260 |
Entity Incorporation State Country Code | DE |
Entity Tax Identification Number | 11-3131700 |
Entity Address, Address Line One | 3854 American Way |
Entity Address, Address Line Two | Suite A |
Entity Address, City or Town | Baton Rouge |
Entity Address, State or Province | LA |
Entity Address, Postal Zip Code | 70816 |
City Area Code | (225) 292-2031 or (800) |
Local Phone Number | 467-2662 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | AMED |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
H_ 0 / ( \ ( !7! 'AL
M+W=O
MU1$\X;CCVE$\]X:BG4^Z
M"N@IW,J:^I(J^W1L_-E_L;]C\<>I%"_UVJLP>H($E,"'B@FL>S6H.GFJZJ(:[J+2NS?23I\)
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MEX!B+$V0F<^KBU$7+EZ=(9;E\NMK_@G=SVF^A'P>AB&S+B669:
M.>3+M'URR$J7;+)YRZQ